Protagonist Therapeutics (PTGX) P/S ratio

P/S ratio today
172.2×

Protagonist Therapeutics (PTGX) trades at 172.2× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 120.7×. That is 1986.8% higher than the 5.8× of fiscal 2024. Figures as of 18 Nov 2026, 09:41 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
172.2×
P/S ratio, fiscal 2025
120.7×
Change on fiscal 2024
+1986.8%
Highest on record
120.7×fiscal 2025
Lowest on record
5.8×fiscal 2024
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Protagonist Therapeutics P/S ratio, in more detail

Today's figure is 42.7% above the fiscal 2025 year-end.

Across the 6 fiscal year-ends on record (2020–2025), the highest was 120.7× in fiscal 2025 and the lowest 5.8× in fiscal 2024. Today's P/S ratio is above every one of the 6 fiscal year-ends on record; their median is 23.0×.

History · 6 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Protagonist Therapeutics P/S ratio, year by year

Protagonist Therapeutics (PTGX) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today172.2×—$124.67—
2025120.7× 1,986.8% up$87.34$0.72
20245.8× 73.3% down$38.60$6.68
202321.7× 7.8% up$22.93$1.06
202220.1× 65.2% down$10.91$0.54
202157.9× 139.1% up$34.20$0.59
202024.2×—$20.16$0.83
2019——$7.05—
2018——$6.73—
2017——$20.80—
2016——$21.99—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Protagonist Therapeutics and comparable companies
CompanyP/S ratio
Twist Bioscience TWST16.2×
Protagonist Therapeutics PTGX176.8×
Krystal Biotech KRYS22.7×
10x Genomics TXG11.5×
HealthEquity HQY6.4×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics P/S ratio: questions and answers

What is Protagonist Therapeutics's P/S ratio?

Protagonist Therapeutics (PTGX) trades at 172.2× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 120.7×. That is 1986.8% higher than the 5.8× of fiscal 2024.

Is Protagonist Therapeutics's P/S ratio high or low compared with its own history?

Today's P/S ratio is above every one of the 6 fiscal year-ends on record; their median is 23.0×.

What are the highest and lowest P/S ratio figures on record for Protagonist Therapeutics?

Across the 6 fiscal year-ends on record (2020–2025), the highest was 120.7× in fiscal 2025 and the lowest 5.8× in fiscal 2024.

How is Protagonist Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Protagonist Therapeutics it is on record here for 6 fiscal years, 2020 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/PTGX/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.